<DOC>
	<DOC>NCT00411125</DOC>
	<brief_summary>This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women</brief_summary>
	<brief_title>Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Healthy postmenopausal women Previous treatment with other osteoporosis medication Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>Pharmacokinetics/dynamics</keyword>
	<keyword>Calcitonin</keyword>
</DOC>